BerGenBio SMA50/200 golden cross tests breakout upon new data
ABOUT BERGENBIO
BGBIO
BerGenBio is a clinical-stage oncology company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers.
https://www.bergenbio.com/category/news/
https://www.nordnet.no/fullscreen/news/1001498364-bergenbio-meets-efficacy-endpoint-for-first-stage-of-phase-ii-trial-with-axl-inhibitor-bemcentinib-in-comb-note-this-headline-has-been-truncated?_ga=2.73223123.1526503989.1578902784-92352681.1557919048
Trinity Delta Analysis:
https://www.trinitydelta.org/companies/bergenbio/
BGBIO
BerGenBio is a clinical-stage oncology company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers.
https://www.bergenbio.com/category/news/
https://www.nordnet.no/fullscreen/news/1001498364-bergenbio-meets-efficacy-endpoint-for-first-stage-of-phase-ii-trial-with-axl-inhibitor-bemcentinib-in-comb-note-this-headline-has-been-truncated?_ga=2.73223123.1526503989.1578902784-92352681.1557919048
Trinity Delta Analysis:
https://www.trinitydelta.org/companies/bergenbio/
